Opentrons AI Lab Automation Raises $40M for Autonomous Science

Opentrons Labworks has raised 40 million dollars in a Series E financing round to expand its push into autonomous science, betting that the next leap in research will come not from smarter models alone but from laboratories that can run themselves. The Long Island City company announced the round on October 29, 2026, led by healthcare investor Avego with participation from BroadOak Capital Partners, according to the company announcement reported by Business Wire.

Opentrons AI Lab Automation is the company's central pitch: robots and software that let artificial intelligence systems design an experiment, run it on physical equipment, read the results, and then design the next experiment in a continuous loop. The company says every experiment run on its robots generates structured, reproducible data, a foundation it argues is essential for autonomous science to move from demonstration to routine use.

The funding arrives at a moment when the bottleneck in science has shifted. Frontier models can now generate hypotheses and draft experimental protocols far faster than laboratories can test them, according to the company. Scientists still spend much of their working day on manual work that a robot can do, a point chief executive James Atwood made in the announcement. Opentrons AI Lab Automation aims to close that gap by connecting AI-generated plans directly to physical execution.

What the Series E will fund

Opentrons said the new capital will scale its robotics, software, and data infrastructure tools, and support expansion into new markets and geographies. The company plans to invest in AI-driven experimental execution, extend its automation capabilities, and build out the data layer that turns individual lab runs into a reusable record of what was tried, what worked, and what should be tried next.

The Opentrons Flex platform sits at the center of that plan. It combines laboratory robots with software and AI systems that automate experimental workflows, from liquid handling to data capture. Because the platform is built for AI to run experiments directly, according to the company, it can serve as a standard interface between a research team's models and its benches, rather than a one-off automation project for a single lab.

Existing investors include SoftBank Vision Fund and Khosla Ventures, according to reporting on the round. The new round follows years of growth for the company, which was founded in 2014 and has now deployed more than 11,000 robots to laboratories in over 80 countries, according to the announcement. Its customers include 90 percent of the top 20 global pharmaceutical companies, all 20 of the top-ranked United States research universities, and 14 of the 15 largest global biopharmaceutical companies, according to reporting by citybiz.

Why autonomous science matters beyond one company

The Opentrons raise is part of a broader shift in how research gets done. In drug discovery, materials science, and biology, teams are pairing AI planning tools with automated labs to run far more experiments than a human team could manage by hand, and to do so with tighter controls and cleaner records. Opentrons AI Lab Automation fits that trend because reproducibility is the weak link in much of modern science: an experiment that cannot be repeated exactly is hard to build on, no matter how clever the hypothesis behind it.

Structured data is the other half of the story. When a robot runs an experiment, it can log every step, reagent, timing, and measurement in the same format every time. That consistency makes results easier to compare across labs and easier to feed back into AI systems that improve the next round of experiments. Opentrons argues that this data loop, not any single robot, is what makes autonomous science possible at scale.

The same logic is spreading through adjacent parts of the AI economy. Agentic systems are increasingly expected to act in the physical world, not just answer questions, and recent coverage of agentic AI support tools shows how agents are moving from chat interfaces into operational workflows. In the lab, that shift is more demanding, because a wrong step wastes reagents, time, and sometimes irreplaceable samples, which is why Opentrons emphasizes validation, structured records, and human oversight alongside automation.

What to watch next

Three questions will decide whether this round delivers on its promise. The first is whether AI-driven experimental execution can prove itself across many kinds of labs, not just well-funded pharmaceutical sites with standardized workflows. The second is whether new markets and geographies adopt the same open, AI-native approach, or whether local regulations and lab practices fragment the standard Opentrons hopes to set. The third is whether the data infrastructure keeps pace: a fleet of robots is only as useful as the shared record of what those robots learned.

For researchers, the practical takeaway is narrower and more immediate. Labs weighing automation should look past the robot itself and ask how experiments are recorded, how easily a protocol can be rerun, and how directly an AI system can propose, execute, and learn from the next run. Opentrons AI Lab Automation is a bet that those questions, answered well, will define the next decade of discovery, and the 40 million dollar Series E gives the company room to test that bet at a larger scale.

Sources: reporting by Business Wire, citybiz, and RoboticsTomorrow, plus related coverage of coordinated AI safety work among leading labs.